Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion

🌐 Bloomberg (United States) —

AI Summary

Novartis plans to license an mRNA-based autoimmune therapy from China’s Abogen Biosciences. The deal could be worth up to $7.8 billion.

Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.

Deals Health Novartis Abogen Biosciences mRNA therapy autoimmune disease licensing deal biopharmaceuticals

Read original source →